NuScale Power's stock plummeted 5.02% to $X.XX intraday Friday, underperforming the broader market, as analysts raised concerns about the company's ability to successfully commercialize its small modular nuclear reactor technology.

On March 3rd, Wall Street analyst Neil Kalton revisited his coverage of NuScale Power, citing challenges and skepticism surrounding the company's commercialization prospects. Kalton highlighted issues such as regulatory hurdles, financing challenges, and doubts over the technology's cost-competitiveness and scalability.

Adding to the bearish sentiment, investment bank UBS adjusted its price target for NuScale Power down to $17 from $25 on Friday morning, while maintaining a Neutral rating on the stock. UBS echoed some of the same concerns raised by Kalton, noting risks around regulatory approvals, construction delays and cost overruns that could impact NuScale's path to commercial viability.